Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study of Amivantamab in People With Esophagogastric Cancer

ClinicalTrials.gov ID: NCT05117931

Public ClinicalTrials.gov record NCT05117931. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 5:19 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.

Study identification

NCT ID
NCT05117931
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
25 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2, 2021 (Actual)
Primary completion
Nov 2026 (Estimated)
Completion
Nov 2026 (Estimated)
Last update posted
Feb 17, 2026

2021 – 2026

United States locations

U.S. sites
9
U.S. states
4
U.S. cities
9
Facility City State ZIP Site status
University of California, Irvine Irvine California 92697 —
Massachusetts General Hospital (Data Collection Only) Boston Massachusetts 02114 —
Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown New Jersey 07748 —
Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale New Jersey 07645 —
Memorial Sloan Kettering Commack (Limited Protocol Activities) Commack New York 11725 —
Memorial Sloan Kettering Westchester (Limited Protocol Activities) Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York New York 10065 —
Memorial Sloan Kettering Nassau (Limited protocol activities) Rockville Centre New York 11553 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05117931, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2026 · Synced Nov 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05117931 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →